Cell therapy

#3D modelling #Cancer research #Cell therapy #Tumour biology

Prostate cancer therapy may fuel spread of bone tumours 

Anti-androgen therapy is commonly used to treat patients with advanced prostate cancer which has spread to the bones, however, the treatment may be fuelling bone cancer spread.  Dr Nathalie Bock from QUT Centre for Biomedical Technologies focused her research on bone metastases from breast and prostate cancers. Read More

#Cancer Research #News

#Cell therapy #Diabetes #Drug development #Immunology #Life sciences

Dundee professor joins GSK’s Immunology Network 

Professor of Cellular Immunology at the University of Dundee’s School of Life Sciences, Doreen Cantrell, has been selected to join GSK’s Immunology Network, a programme designed to embed academic scientists in GSK laboratories with the goal to broaden scientific insight and drive major breakthroughs in applied immunology. … Read More

#News

#CAR-T #Cell therapy #GlobalData #Oncology #Tumour biology

Off-the-shelf potential for NK cell therapies for tumour treatment 

Natural killer (NK) cell therapies have the potential to be an effective, off-the-shelf treatment for a range of cancers. Analysis of NK cell therapies, currently in development, reveals that 57% of these are allogeneic therapies, and although development in haematological indications is more advanced, there are a high number of therapies… Read More

#Cancer Research #News

#Cell therapy #Clinical trials #Covid-19 #Drug development #Drug discovery #Drug targets #Stem cells #Therapeutics

Exploring iPSCs for individual and population health applications

Listen to this article on the DDW Podcast: Brad Hamilton, Founder and Chief Science Officer at GoodCell examines the potential of induced Pluripotent Stem Cells. Across the world, patients suffering from heart failure, donor organ rejection and many other life-altering illnesses are struggling to combat the symptoms of their conditions. What… Read More

#Editor's Choice #Exclusive Content #News

Cancer research
#Cancer #Cancer research #Cell therapy #Clinical trials #Oncology

The personal touch: the scientist making an impact in cancer research

Listen to this article on the DDW Podcast: At 33, Martyn Hiscox is an inspiration to scientists in oncology research. Principal scientist with Adaptimmune, a UK cell therapy biotech, Lu Rahman uncovers Hiscox’s passion, dedication and the personal reason for developing cell therapy treatments for cancer. Hiscox clearly has immense respect… Read More

#Cancer Research #Editor's Choice #Exclusive Content #News

#CAR-T #Cell therapy

Bioelectronic assays: Setting a standard for potency measurement

Bioelectronic assays allow scientists to precisely and continuously monitor cultured cells without labels or dyes. Dr Jim Ross, Chief Technology Officer and co-founder of Axion Biosystems, elaborates. Young industry, massive momentum Although cell-based immunotherapies for cancer treatment are relatively new, they are poised to take the biomedical world by storm. Read More

#Exclusive Content #News

#Biologics / Biotechnology #CAR-T #Cell therapy #Immunotherapy #Stem cells

Biotech’s pursuit of next-generation CAR-T

Listen to this article on the DDW Podcast: Pierre-Louis Joffrin leads Corporate Development at Mogrify. He examines immunotherapies including an assessment of the next generation of stem cell derived products. Biotech has joined the pursuit of next-generation CAR-Ts and it’s not subtle. Some new, others having pivoted towards the area, there… Read More

#Cancer Research #Editor's Choice #Exclusive Content #News

#Cell and gene therapy #Cell and Gene Therapy Catapult #Cell therapy

CGT Catapult to expand to Edinburgh BioQuarter

The Cell and Gene Therapy Catapult (CGT Catapult) is setting up offices and laboratories in Edinburgh, Scotland. With this expansion, CGT Catapult aims to provide additional, regionally focused support to the cell and gene therapy sector to accelerate product development, clinical trials and adoption. CGT Catapult Edinburgh is a collaboration… Read More

#News

#Cancer research #CAR-T #Cell therapy #Drug development #Immuno-oncology

Innovation driving cell therapies toward the clinic

Sean Chang, Product Manager, Cell and Gene Therapy at Thermo Fisher Scientific It has been four years since the first Chimeric Antigen Receptor T-cell (CAR T) therapy drug, Kymriah1, was approved by the US Food and Drug Administration (FDA) for the treatment of B-cell acute lymphoblastic leukaemia (ALL). Since then,… Read More

#Exclusive Content #News

#Biotherapeutics #Cancer research #CAR-T #Cell therapy #Clinical trials #Drug development

Aleta and Cancer Research UK to advance blood cancer therapy

Aleta Biotherapeutics and Cancer Research UK have collaborated to advance the early phase clinical development of Aleta’s CAR-T cell engager candidate, ALETA-001. Under the terms of the clinical development partnership, Cancer Research UK’s Centre for Drug Development will fund, sponsor and conduct the first-in-human Phase I/IIa clinical trial of ALETA-001,… Read More

#News

#Biotherapeutics #Cell therapy #FDA #Tumour biology

What FDA Clearance means for GammaDelta cell cancer therapy

GammaDelta Therapeutics’ Investigational New Drug (IND) application has been cleared by the US Food and Drug Administration (FDA) for its allogeneic variable delta 1 (Vδ1) gamma-delta (γδ) T cell therapy, GDX012, to be investigated as a treatment for haematological malignancies. The FDA also granted orphan drug designation to allogeneic Vδ1… Read More

#News

#Antibodies #Cell therapy #Drug design #Drug technology #Protein Fluidics #Software

Updated platform helps streamline workflows

Sphere Fluidics has enhanced the capability and performance of its Cyto-Mine System. This is an automated platform which integrates single cell screening, sorting, dispensing, imaging and clone verification. The simplified design should help streamline workflows, reduce costs, increase throughput, and enable high-value clones to be captured in a single run. Read More

#News

#Antibodies #Cell therapy #DNA #Drug delivery #Drug development #Drug discovery #Sequencing

Accelerating antibody discovery by making sequence space accessible

The biggest constraint in discovering new antibodies for immunotherapy is constructing the underlying DNA sequence, says Dr. Aaron Sato, CSO of Twist Bioscience. Inside the human body, the immune system generates antibodies that can target just about any foreign molecule. It does so through DNA recombination and somatic hypermutation –… Read More

#Editor's Choice #Exclusive Content #News

#Biotechnology #Cell and gene therapy #Cell therapy #Genetics

Partnership to advance diversified gene therapy pipeline

Gene therapy company AavantiBio and Catalent, technologies, development, and manufacturing solutions service, have partnered to support the development and manufacturing of AavantiBio’s gene therapies, including Friedreich’s Ataxia (FA). Catalent will provide process development and CGMP manufacturing of AavantiBio’s adeno-associated viral (AAV) vector-based therapeutic candidate for use in clinical trials in the… Read More

#News

#Biotechnology #Cell and gene therapy #Cell therapy #Drug development #Drug discovery

ATMPS and Ori Biotech collaborate for cell and gene therapy developers

ATMPS, provider of blockchain-based “vein to vein” cell orchestration platforms for advanced therapies, and Ori Biotech, an innovator in cell and gene therapy (CGT) manufacturing platforms, have teamed up to create integration between their data platforms to support the development of advanced therapies. The partnership will result in the integration… Read More

#News

#Awards #Cell therapy #Drug development #Therapeutics

Mogrify wins awards for innovation and named business of the year

Mogrify, a UK company which aims to transform the development of ex vivo cell therapies and pioneer the field of in vivo reprogramming therapies, has been awarded the Hewitsons Award for Innovation in Business and Price Bailey Award for Business of the Year at the CambridgeshireLive Business Excellence Awards 2020. Read More

#News